First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO
GALAXY study data shows Signatera predicts colorectal cancer survival, with a 10x advantage at 36 months for ctDNA-negative patients and a 50% reduced risk of death for Signatera-positive patients on adjuvant chemotherapy.
Reference News
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO
GALAXY study data shows Signatera predicts colorectal cancer survival, with a 10x advantage at 36 months for ctDNA-negative patients and a 50% reduced risk of death for Signatera-positive patients on adjuvant chemotherapy.